You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
聯環藥業(600513.SH):亞中製藥擬投資生物醫藥研發製造基地項目
格隆匯 12-27 19:29

格隆匯12月27日丨聯環藥業(600513.SH)公佈,公司控股子公司成都亞中生物製藥有限責任公司(以下簡稱“亞中製藥”)為滿足日益增長的市場需求、解決發展瓶頸,根據公司發展及戰略佈局,擬與四川省彭州工業開發區管理委員會簽訂《投資協議》,投資生物醫藥研發製造基地項目。

項目分兩批次建設,一批次完成約90畝佔地面積的建設,預計2021年底完成原料藥生產線和一條固體制劑生產線的建設並投產;二批次作為公司的長遠戰略儲備,開工投產時間視一批次項目建設、製劑產品情況、研發進展等情況確定,初步預計2023年6月底完成約60畝佔地面積的建設並投產。項目距離正式生產時間較長,具有較大不確定性。

一批次項目預計將建成產能為800噸的地奧司明原料藥生產線、產能為10噸的麥角甾醇原料藥生產線和一條固體制劑生產線。

亞中製藥是一家專業從事於植物提取,化學合成的醫藥原料藥生產企業。其主要產品地奧司明主要是用於治療靜脈疾病的口服全血藥物,於2014年4月2日註冊,藥品標準編號為:YBH01272014,藥品批准文號為:國藥準字H20143088,藥品批准文號有效期至2019年4月1日。並於2018年11月27日再註冊,藥品批准文號有效期延長至2023年11月26日。於2015年2月28取得了地奧司明生產車間藥品GMP證書,證書編號:SC20140104,有效期至2020年2月27日。麥角甾醇是生產維生素D2的前體,也是生產激素類藥物的中間體,可用來生產可的鬆。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account